A retrospective study comparing the efficacy of a lower dose of abiraterone acetate 250 mg per day with food to the standard regimen abiraterone acetate 1000 mg per day on an empty stomach. Real-world data, prostate cancer, abiraterone acetate
Conditions
Interventions
These are patients with metastatic castration-resistant prostate cancer mCRPC treated with abiraterone 250 mg per day with food and registered in the OCPA program.
Treatment
Sponsors
None listed
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: An enrollment was collected based on data from the OCPA registry. 1. These are patients with metastatic castration-resistant prostate cancer mCRPC treated with abiraterone 250 mg per day with food and registered in the OCPA program from June 28, 2022, to November 30, 2024. 2. Age 18 years or older at diagnosis. 3. Diagnosis of metastatic castration-resistant prostate cancer; serum testosterone level less than 50 ng per dl. 4. Treated with abiraterone 250 mg per day with food and registered in the OCPA program.
Exclusion criteria
Exclusion criteria: 1. Patients registered in the OCPA program with incomplete clinical data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival day days | — |
Secondary
| Measure | Time frame |
|---|---|
| PSA Response months Percentage | — |
Countries
Thailand
Contacts
Public ContactPhichai Chansriwong
Ramathibodi Hospital
Outcome results
None listed